Noxxon Expands Clinical Trial Despite COVID-19

Noxxon Pharma has expanded its clinical trial of NOX-A12 with radiotherapy in brain cancer patients despite delays due to the COVID-19 pandemic.

The drugmaker said that all centers will continue treatment of already enrolled patients and two of its three centers are recruiting new patients as planned.

Noxxon said it plans to add centers to the trial to increase recruitment capacity. It said staff will replace face-to-face meetings with virtual meetings where possible.